![]() |
|
|
|||||||
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
BioMimetic Therapeutics, Inc. announced today that it received a comprehensive post-panel response letter from the FDA related to the Company's Pre-Market Approval application for AugmentŪ Bone Graft for use as an alternative to autograft in hindfoot and ankle fusion procedures.
|
| Thread Tools | |
| Display Modes | |
|
|